(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 0.83% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.5%.
Teva Pharmaceutical Industries's revenue in 2023 is $15,273,000,000.On average, 6 Wall Street analysts forecast TEVA's revenue for 2023 to be $17,208,091,696,289, with the lowest TEVA revenue forecast at $17,101,884,158,785, and the highest TEVA revenue forecast at $17,270,803,309,214. On average, 6 Wall Street analysts forecast TEVA's revenue for 2024 to be $17,199,660,871,879, with the lowest TEVA revenue forecast at $16,785,871,167,229, and the highest TEVA revenue forecast at $17,545,441,253,704.
In 2025, TEVA is forecast to generate $17,621,054,124,193 in revenue, with the lowest revenue forecast at $17,280,667,855,792 and the highest revenue forecast at $17,913,131,017,672.